Welcome to our dedicated page for Beta Bionics news (Ticker: BBNX), a resource for investors and traders seeking the latest updates and insights on Beta Bionics stock.
News and updates for Beta Bionics, Inc. (Nasdaq: BBNX) focus on its role as a commercial-stage medical device company developing advanced diabetes management solutions. The company’s press releases highlight the iLet Bionic Pancreas, described as the first FDA-cleared insulin delivery device that autonomously determines every insulin dose for insulin-requiring people with diabetes.
Investors following BBNX news will see regular announcements of quarterly financial results, including net sales, gross margin, operating loss, net loss, and adjusted EBITDA. These updates also report operational metrics such as installed customer base, new patient starts, and the proportion of new patient starts coming from multiple daily injections or reimbursed through the pharmacy benefit plan channel.
Beta Bionics’ news flow also includes guidance updates for full-year revenue, gross margin, and channel mix, as well as details on its multi-channel reimbursement efforts. The company has reported formulary agreements with major pharmacy benefit managers and describes how coverage decisions can affect up-front pump costs and prescribing logistics for the iLet Bionic Pancreas.
Another key theme in BBNX news is clinical and real-world evidence. The company has issued press releases and filed 8-Ks describing real-world iLet data from thousands of users, including changes from baseline HbA1c to glucose management indicator, hypoglycemia measures, and outcomes for users transitioning from multiple daily injections or competitive hybrid-closed loop systems.
News items also cover strategic and development milestones, such as the glucagon PK-PD bridging trial in Canada for the bihormonal configuration of the iLet, plans for feasibility trials, and an agreement to integrate the iLet automated insulin delivery system with Abbott’s future dual glucose-ketone sensor. In addition, Beta Bionics announces participation in healthcare and investor conferences and provides information on webcasts and presentations.
For investors and observers, the BBNX news page offers a centralized view of financial performance, adoption trends, clinical data disclosures, and product development updates related to the iLet Bionic Pancreas platform.
Beta Bionics (Nasdaq: BBNX) reported strong Q2 2025 financial results, with net sales reaching $23.2 million, up 54% year-over-year. The company's installed customer base grew 200% to 24,085 users, with 4,934 new patient starts in Q2. The company achieved significant growth in both DME and PBP channels, with PBP channel sales surging 498% to $4.6 million.
Key operational metrics showed improvement with gross margin reaching 53.8%. Despite growth, the company reported a net loss of $16.9 million. Beta Bionics raised its full-year 2025 guidance, projecting revenue of $88-93 million, up from previous guidance of $82-87 million.
Strategic highlights include securing formulary agreements with major PBMs and completing dosing in the glucagon PK-PD bridging trial for their bihormonal configuration development.
Beta Bionics (Nasdaq: BBNX), a leader in advanced diabetes management solutions, will release its Q2 2025 financial results on Tuesday, July 29, 2025, after market close. The company will host a conference call and webcast at 4:30 PM ET on the same day.
Investors can access the webcast through the company's investor relations website under the "Events & Presentations" section, where it will also be archived for future viewing. For those joining by phone, registration is available through a dedicated link that will provide dial-in details and a personal pin.
[]Beta Bionics (BBNX), a company focused on diabetes management solutions, has announced its participation in the upcoming Bank of America Securities Health Care Conference. The presentation is scheduled for Tuesday, May 13, 2025, at 12:35 PM ET (9:35 AM PT) in Las Vegas. Interested parties can access the live audio webcast through the company's investor relations website under the "Events & Presentations" section at investors.betabionics.com. The presentation recording will be archived on the website for future viewing.
Beta Bionics (Nasdaq: BBNX), a leader in advanced diabetes management solutions, has scheduled the release of its first quarter 2025 financial results for Tuesday, May 6, 2025, after market close.
The company will host a conference call and simultaneous webcast at 4:30 PM Eastern Time (1:30 PM Pacific Time) on the same day. Investors can access the live call by dialing (888) 596-4144 with passcode 8363701. The webcast will be available in the Investors—Events & Presentations section of the company's website and will be archived for future viewing.
Beta Bionics (Nasdaq: BBNX) has announced an upcoming investor event scheduled for June 22, 2025, in Chicago, coinciding with the 85th Scientific Sessions of the American Diabetes Association. The event will run from 7:00 AM to 8:30 AM Central Time.
The presentation will feature:
- Commercial and financial performance updates
- Demonstration of new patch pump development
- Review of adaptive closed-loop algorithm
- Presentation of new real-world clinical data
The event will be accessible via live webcast through the company's investor relations website. In-person attendance requires registration through Beta Bionics' IR representative. A replay of the webcast and presentation materials will be available on the company website after the event.
Beta Bionics (Nasdaq: BBNX), a leader in advanced diabetes management solutions, has appointed Gerard Michel as an independent board director effective March 26, 2025. Michel, currently CEO of Delcath Systems (Nasdaq: DCTH), brings over 30 years of pharmaceutical and medical technology industry experience.
Michel's extensive background includes serving as CFO at Vericel , CFO and VP of Corporate Development at Biodel Inc. (2007-2014), and similar roles at NPS Pharmaceuticals (2002-2007). He previously held positions at Booz Allen and worked in commercial roles at Lederle Labs and Wyeth Labs.
Michel holds an M.S. in Microbiology from the University of Rochester School of Medicine, an M.B.A. from Simon School of Business, and dual B.S. degrees in Biology and Geology.
Beta Bionics (NASDAQ: BBNX) reported strong Q4 and full-year 2024 financial results. Q4 net sales reached $20.4M, up 145% YoY, with DME channel sales of $18.1M (+127%) and PBP channel sales of $2.4M (+491%). The installed customer base grew to 15,298 users (+564%).
Full-year 2024 showed net sales of $65.1M (+443% YoY), with DME channel sales of $58.8M and PBP channel sales of $6.3M. The company completed an IPO raising $206M and launched the Color iLet Bionic Pancreas with FreeStyle Libre 3 Plus integration.
For 2025 guidance, Beta Bionics expects revenue of $80-85M, with over 20% of new patient starts through PBP channel and gross margin of at least 50%. The company ended 2024 with $103.6M in cash and equivalents.
Beta Bionics (NASDAQ: BBNX), a leader in advanced diabetes management solutions, has scheduled the release of its Q4 and full year 2024 financial results for March 25, 2025, after market close.
The company will host a conference call and webcast at 4:30 PM ET (1:30 PM PT) on the same day to discuss the financial performance. Investors can access the webcast through the company's investor relations website, and a replay will be available afterward.